Starzl T E, Murase N, Demetris A, Trucco M, Fung J
Transplantation Institute, Departments of Surgery, Pathology, and Pediatrics, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, USA.
Semin Liver Dis. 2000;20(4):497-510. doi: 10.1055/s-2000-13158.
The evolution of clinical transplantation has hinged on 2 seminal turning points. The first was the demonstration in 1953 by Billingham, Brent, and Medawar that chimerism-associated tolerance could be induced deliberately in neonatal mice by infusing adult donor hematolymphopoietic cells. This discovery escalated in a straight line over the next 15 years to successful bone marrow transplantation in humans. The second turning point was the demonstration that organ allografts could self-induce tolerance under an umbrella of immunosuppression, or in some species without immunosuppression. Unfortunately, it was incorrectly concluded by most immunologists and surgeons that bone marrow and organ engraftment involved different immune mechanisms. In a derivative error, it became widely believed that the tolerogenicity of the liver differed fundamentally not only from that of bone marrow but also from that of other whole organs. These errors became dogma and were not corrected until low level donor leukocyte chimerism was found in humans and animals bearing long surviving liver, kidney, heart, and other kinds of allografts. With successful bone marrow transplantation, the trace population consisted of recipient rather than donor leukocytes. Thus, the consequences of organ and bone marrow engraftment were mirror images. From these observations, it was proposed that the engraftment of all kinds of organs as well as bone marrow cells (BMC) involved host versus graft (HVG) and graft versus host (GVH) reactions with reciprocal induction of variable degrees of specific non-reactivity (tolerance). The maintenance of the tolerance was an active and ongoing process requiring the persistence of the transplanted fragment of the donor immune system. The immune responsiveness and unresponsiveness to both organ and bone marrow allografts are thought to be governed by the migration and localization of leukocytes. The clarifying principles of tranplantation immunology that have emerged from the chimerism studies are relevant to the adaptive immune response to microbial, tumor, allogeneic, and self antigens. These principles should be used to guide efforts to systematically induce tolerance to human tissues and organs, and perhaps ultimately to xenografts.
临床移植的发展取决于两个具有开创性的转折点。第一个转折点是1953年比林厄姆、布伦特和梅达沃证明,通过输注成年供体的血液淋巴细胞,可以在新生小鼠中故意诱导与嵌合体相关的耐受性。这一发现在此后的15年里直线发展,最终实现了人类骨髓移植的成功。第二个转折点是证明器官同种异体移植可以在免疫抑制的保护伞下自我诱导耐受性,或者在某些物种中无需免疫抑制即可实现。不幸的是,大多数免疫学家和外科医生错误地得出结论,认为骨髓移植和器官移植涉及不同的免疫机制。在一个衍生错误中,人们广泛认为肝脏的耐受性不仅与骨髓的耐受性根本不同,而且与其他整个器官的耐受性也根本不同。这些错误成为了教条,直到在长期存活的肝脏、肾脏、心脏和其他同种异体移植的人类和动物中发现低水平的供体白细胞嵌合体,这些错误才得以纠正。在成功的骨髓移植中,微量细胞群由受体而非供体白细胞组成。因此,器官移植和骨髓移植的结果是相反的。基于这些观察结果,有人提出,各种器官以及骨髓细胞(BMC)的移植涉及宿主对移植物(HVG)和移植物对宿主(GVH)反应,并相互诱导不同程度的特异性无反应性(耐受性)。耐受性的维持是一个活跃且持续的过程,需要供体免疫系统移植片段的持续存在。对器官和骨髓同种异体移植的免疫反应性和无反应性被认为受白细胞迁移和定位的控制。从嵌合体研究中得出的移植免疫学的明确原则与对微生物、肿瘤、同种异体和自身抗原的适应性免疫反应相关。这些原则应用于指导系统性诱导对人体组织和器官耐受性的努力,也许最终还可用于指导对异种移植的耐受性诱导。